Search

Your search keyword '"Huleux, Thomas"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Huleux, Thomas" Remove constraint Author: "Huleux, Thomas" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
49 results on '"Huleux, Thomas"'

Search Results

4. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial

5. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial

7. Impact of the COVID-19 pandemic on sexual behaviour and welfare of HIV preexposure prophylaxis users: a mixed-method study.

12. In-Depth Characterization of Full-Length Archived Viral Genomes after Nine Years of Posttreatment HIV Control

13. Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers

15. Smoking‐associated morbidities on computed tomography lung cancer screens in HIV‐infected smokers

17. High syphilis prevalence and incidence in people living with HIV and Preexposure Prophylaxis users: A retrospective review in the French Dat’AIDS cohort

18. A highly virulent variant of HIV-1 circulating in the Netherlands

19. Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France

20. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial

21. History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic

23. No barrier to care, yet disparities in the HIV care continuum in France: a nationwide population study

24. Assessment of intra-sample variability in HIV-1 DNA drug resistance genotyping

25. Spectrum and Incidence Trends of AIDS- and Non–AIDS-Defining Cancers between 2010 and 2015 in the French Dat'AIDS Cohort

26. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018

27. Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015

29. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial

30. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012–2018.

32. Additional file 2: Figure S1. of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

33. Additional file 4: Figure S3. of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

34. Additional file 8: Figure S7. of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

35. Additional file 5: Figure S4. of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

36. Additional file 6: Figure S5. of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

37. Additional file 3: Figure S2. of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

38. Additional file 1: of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

39. Clinical and virological features of acute hepatitis A during an ongoing outbreak among men who have sex with men in the North of France

40. Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV

41. Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study

42. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients – “En route for eradication”?

43. Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.

44. Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients.

45. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination.

46. Clinical and virological features of acute hepatitis A during an ongoing outbreak among men who have sex with men in the North of France.

47. Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.

48. No barrier to care, yet disparities in the HIV care continuum in France: a nationwide population study.

49. Initiation of Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring Hospitalization.

Catalog

Books, media, physical & digital resources